European Innovation Council

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

RespiQ is a healthtech company developing portable, non-invasive breath analysis technology that uses emission spectroscopy and artificial intelligence to detect biomarkers in breath for early identification and real-time monitoring of respiratory diseases such as COPD, as well as other conditions like asthma, lung cancer, and infectious diseases. Its device aims to be affordable and user-friendly, democratizing access to advanced diagnostics, while its platform can also identify digestive issues through breath biomarkers and support personalized guidance via an app that analyzes a digital breath print to deliver diet and health insights, enabling individuals to monitor changes and improve health outcomes.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.

ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

Inbiome is a trailblazing company in molecular diagnostics, specializing in proprietary molecular culture technology. This innovation enables swift bacterial testing and microbiome analysis, significantly expediting the process compared to traditional methods. The company's primary mission is to advance clinical microbiology by focusing on microbial detection and product development, thereby guiding clinicians towards more accurate and timely diagnoses. By offering advanced molecular technology for microbiome analysis, Inbiome aids in enhancing the understanding of bacteria in the human body, facilitating correct treatments, and mitigating unnecessary complications, costs, and anti-microbial resistance.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly in the realm of MRI technology. The company manufactures cylindrical phantoms that streamline the preparation process by eliminating the need for multiple sample vials, facilitating more efficient calibration. Its offerings include a cloud-based data analysis platform that ensures traceability to standardized values, allowing clinicians, medical physicists, and radiographers to obtain consistent quantitative measurements of diseases across different patients, scanners, and clinical environments. By enhancing the precision of MRI imaging, Gold Standard Phantoms aims to improve diagnostic accuracy and potentially reduce healthcare costs.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Afon Technology specializes in the development of non-invasive blood glucose monitoring devices aimed at benefiting individuals with diabetes. The company’s innovative technology allows for real-time, pain-free tracking of blood glucose levels, offering features such as continuous detection, potential pre-diabetic identification, and alarm alerts for high and low glucose levels. Users can access trend profiles and time-in-range statistics through a user-friendly app compatible with both iOS and Android systems. Additionally, Afon Technology’s device can transform any smartwatch into a glucose monitoring tool, providing fast and accurate measurements, data logging, and personalized health trends. This approach enhances daily management for diabetics, ultimately reducing the risk of diabetes-related complications.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

Brainhero offers home-based neurofeedback therapy using EEG technology. It aims to help children manage symptoms of Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) through engaging, app-based brain training.

Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

Nanordica Medical is an Estonian medical technology company that develops wound care solutions based on patented nanotechnology, combining copper and silver in nanofibers to remove infection and support healing in chronic wounds. The company has launched a veterinary wound dressing and is developing a first-in-class human dressing for hard-to-heal wounds such as diabetic foot ulcers. Clinical data suggest superior efficacy of the Nanordica dressing compared with conventional silver-based dressings. The underlying technology uses silver nanoparticles blended with other components to broaden antibacterial activity, including against drug-resistant strains.

Nexdot is a company specializing in the development and production of semiconductor nanocrystals known as Quantum Dots, with a particular focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Originating as a spin-off from a renowned academic laboratory in Paris, Nexdot leverages over a decade of expertise in nanomaterial research. The company has invested four years in intensive research and development to establish unique capabilities in the synthesis of colloidal Quantum Dots and Nanoplatelets. Their proprietary materials, characterized by controlled shape and composition, are designed for a variety of applications, including displays, lighting, energy storage, detectors, and bio-imaging. Nexdot combines a team of highly skilled, passionate scientists with seasoned executives who possess a strong background in management and innovation leadership, positioning the company as a leader in the field.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

Sightic Analytics specializes in developing AI-powered software that enables real-time analysis of drug effects through image analysis of the eye area. Utilizing a mobile phone's camera, the company's technology captures a short film sequence of an individual's eye, focusing on pupil responses to detect the presence of drugs. This innovative approach allows for efficient and discreet drug testing, making it suitable for use in various settings, including workplace environments. Sightic's solution aims to streamline the drug screening process while minimizing privacy concerns, enabling employers to monitor employee health effectively.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Born from the MRCLEAN trial, NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center. Our research background continues to drive our way of thinking. The team consists of researchers, developers and experienced medical specialists to ensure we align with our clients needs. We believe connecting human & artificial intelligence will revolutionize emergency care. Our cloud-based solution, StrokeViewer, automatically analyses brain CT scans and gives results within minutes. StrokeViewer empowers physicians in the emergency setting to provide patients with the right treatment in time.

Kahun is a healthcare technology company that offers an online medical platform designed to assist physicians in making informed clinical decisions. By cataloging clinical information from peer-reviewed medical literature, Kahun's platform employs artificial intelligence diagnostic engines to extract relevant insights. This approach not only streamlines the clinical intake process but also enhances the transparency and explainability of healthcare decisions. By optimizing physicians' documentation time and overall cognitive load, Kahun aims to improve clinical outcomes and facilitate faster, evidence-based decision-making within healthcare organizations.

Restore Medical develops a device-based therapy for congestive heart failure. Its product, ContraBand, is a catheter-delivered implant in the pulmonary arteries designed to improve patient quality of life and reduce hospital readmission rates.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

Metafora Biosystems is a biotechnology company focused on developing innovative and unmatched ligands known as receptor-binding domains (RBDs) for nutrient transporters. These tools enable the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. The company's technology offers multiple competitive advantages across various segments of the biomarker market, positioning it as a valuable player in the field of metabolic research and diagnostics.

Oivi is a Norwegian company founded in 2017 and based in Oslo, specializing in the development of an affordable AI-driven camera and platform for the identification of diabetic eye diseases. The company focuses on facilitating retinal screening in primary care settings, thereby promoting awareness and proactive management of diabetic eye health. Oivi's innovative platform employs automated image capture and diagnostic capabilities to monitor eye diseases effectively through teleconsultation. With a multifaceted team possessing extensive expertise in camera and software development, Oivi aims to empower patients to prevent permanent vision loss associated with diabetes.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Metafora Biosystems is a biotechnology company focused on developing innovative and unmatched ligands known as receptor-binding domains (RBDs) for nutrient transporters. These tools enable the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. The company's technology offers multiple competitive advantages across various segments of the biomarker market, positioning it as a valuable player in the field of metabolic research and diagnostics.

Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

OxyPrem AG is a Swiss company that specializes in the development, design, and manufacturing of advanced sensor solutions specifically for monitoring preterm infants. Established in 2018 and headquartered in Zurich, the company offers a reusable device that continuously measures hemoglobin oxygen saturation in the brains of high-risk preterm infants. By utilizing harmless near-infrared light technology, OxyPrem provides real-time monitoring, which significantly enhances the clinical care provided to this vulnerable patient group. The innovations from OxyPrem aim to prevent early death and severe long-term brain damage, thereby minimizing the risk of disabilities and other complications associated with premature birth.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Dermagnostix is a German company founded in 2020, located in the Freiburg and Munich areas. It specializes in developing innovative dermatology diagnostics aimed at enhancing clinical practice and improving patient experiences. The company offers a molecular diagnostic platform that facilitates rapid and objective diagnostics for skin diseases, particularly in distinguishing between eczema and psoriasis at a molecular level. This technology empowers healthcare professionals to provide better care and treatment options, ultimately improving the lives of patients with dermatological conditions.

Peili Vision develops a virtual reality platform for neurological rehabilitation. The platform enables therapists to design customizable training environments for speech and language pathology, neuropsychology, and occupational therapy, and integrates data analytics, gamification, remote rehabilitation, feedback, and therapy-session services for private and public healthcare clients. The solution supports hospital and home-based rehabilitation by combining virtual reality, data, and gamification to tailor exercises, monitor patient progress, and provide outcomes to clinicians. Founded in 2015 and based in Helsinki, Finland, with an additional office in Oulu, Peili Vision aims to help patients regain daily functioning through immersive, patient-centered therapeutic exercises.

Thericon is a medical technology company specializing in multiparametric imaging solutions for surgical procedures. It offers a proprietary system that helps surgeons distinguish various tissue types and identify malignant lesions, enhancing surgical accuracy and aiding in informed treatment decisions.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

InVera Medical specializes in developing innovative medical devices focused on treating chronic venous disease. Their flagship product, BioVena™, offers a less invasive, pain-free solution for varicose veins and venous ulcers, utilizing the body's natural biological response.

Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.

Aligned Bio specializes in developing advanced biosensor platforms using patented nanowire production methods. Their sensors are designed for applications such as biomedicine, water purification, public safety, and electronics, offering high sensitivity, accuracy, and speed.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

Xsensio is a digital health company focused on revolutionizing healthcare monitoring. It specializes in developing a wearable, Lab-on-Skin© platform that continuously analyzes biochemical data from the skin's surface in real-time, offering unprecedented insights into health and wellness.

Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Aligned Bio specializes in developing advanced biosensor platforms using patented nanowire production methods. Their sensors are designed for applications such as biomedicine, water purification, public safety, and electronics, offering high sensitivity, accuracy, and speed.

SwissDeCode is a Swiss company based in Renens that specializes in food safety and compliance services for food manufacturers. Founded in 2016, it offers rapid onsite DNA testing solutions that allow production facilities to confirm food authenticity, safety, and origin. By providing plug-and-play systems, SwissDeCode enables factories to obtain food safety and quality certifications within the same work shift, facilitating immediate decision-making for inspectors. This approach not only addresses contamination threats but also transforms them into sustainable opportunities for food producers.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

enGenome is a bioinformatics company that provides accurate omics-based reports to physicians. Its platform automates variant interpretation guidelines, reducing the number of variants of uncertain significance (VUS) and enabling geneticists to detect pathogenic genomic variants with accuracy and speed. This improves diagnosis and treatment processes for patients with genetic diseases.

Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.

Amadix develops cancer diagnostics with a focus on non-invasive screening and early detection. It aims to detect tumors years before symptoms and provide screening signatures in blood to address unmet needs in oncology. Its most advanced product, Colofast, is a blood-based signature for colorectal cancer and advanced adenoma screening, designed to reduce mortality from colon cancer by enabling early intervention. The company pursues analytical validation and demonstration of clinical validity and utility through international multicentre studies, with plans for worldwide commercialization. The leadership combines experience in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property, and independent board members provide guidance on strategy, commercialization, and business development in Europe and the US.

BrainCapture manufactures affordable mobile EEG equipment, focusing on epilepsy detection. It provides a Bluetooth-enabled electrode cap that transmits brain data to the cloud, facilitating remote diagnosis by neurologists, particularly in low- and middle-income countries.

PKvitality is a French bio-wearable company founded in 2017. It specializes in developing non-invasive health monitoring devices, notably the K’Watch Glucose, a smartwatch that enables diabetic patients to monitor their glucose levels painlessly and discreetly.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

NanoVation specializes in developing monitoring solutions for patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease and asthma. The company has created a nanosensor-based wearable device that enables the early detection of subtle changes in a patient's respiratory condition. By identifying these changes before they reach critical stages, NanoVation aims to improve patient outcomes through timely interventions and reduce the risk of exacerbations and unnecessary hospitalizations. Founded by Gregory Shuster, NanoVation focuses on empowering healthcare professionals with the tools needed to monitor patients at home effectively, facilitating proactive measures in respiratory care.

GlucoModicum develops non-invasive glucose monitoring technology to enable continuous glucose measurement without needles. Its platform uses magnetohydrodynamic technology to sample interstitial fluid through the skin, providing rapid, gentle glucose monitoring for individuals with diabetes and healthcare providers to manage blood glucose with less discomfort than traditional finger-prick methods.

Glycanostics is a start-up focused on developing innovative cancer diagnostic tests, specifically targeting prostate cancer. The company specializes in creating clinically validated and registered non-invasive liquid biopsy tests that analyze glycan changes on proteins, such as prostate-specific antigen (PSA). This technology aims to deliver accurate and affordable diagnostic solutions, assisting healthcare professionals in making informed decisions regarding the necessity of biopsies and monitoring patients post-biopsy. Through its advancements in cancer diagnostics, Glycanostics seeks to improve early detection and patient outcomes.

GlucoModicum develops non-invasive glucose monitoring technology to enable continuous glucose measurement without needles. Its platform uses magnetohydrodynamic technology to sample interstitial fluid through the skin, providing rapid, gentle glucose monitoring for individuals with diabetes and healthcare providers to manage blood glucose with less discomfort than traditional finger-prick methods.

Delmic is a company specializing in correlative light and electron microscopy technology, catering to the needs of life and materials science research. It offers a range of advanced services, including cathodoluminescence, integrated and automated cryo-electron tomography workflows, and rapid electron microscopy solutions designed for reliability and high throughput. By providing integrated correlative microscopy, Delmic equips researchers and organizations with effective and user-friendly tools, enabling them to obtain insights more efficiently and with greater ease.

SquareMind is a company focused on revolutionizing oncology care through the development of advanced medical assistants. It specializes in creating robotic medical equipment that enhances non-invasive healthcare practices. The company's innovative technology incorporates third-dimension construction software, allowing for comprehensive full-body mapping to detect skin cancer. This capability enables healthcare professionals to effectively monitor the growth of moles on patients' bodies, utilizing readily available robotic systems. By integrating cutting-edge technology with practical applications in oncology, SquareMind aims to improve early detection and patient outcomes in the field of cancer care.

RadonTec GmbH, founded in 2017 and located in Wittislingen, Bayern, specializes in radon detection and control system solutions aimed at ensuring radon-safe construction. The company develops a comprehensive Radon Detection and Control System (RDC) that employs advanced sensor technology to actively manage ventilation systems and fans. In addition to its primary offerings, RadonTec provides a range of services, including workplace and interior radon measurement, control measurements, and assessments of building materials. This enables customers to obtain reliable radiation measurement devices and accessories tailored for both home and professional applications, promoting safety in environments affected by radon exposure.

Idoven develops an AI-powered cardiology-as-a-service platform that enhances the diagnostic capabilities of cardiologists and non-cardiology clinicians. It partners with prominent organizations like AstraZeneca, Abbott, and GE Healthcare to improve patient care. Idoven has received significant recognition for its innovative technology, including awards from the European Innovation Council and CB Insights.

Smart4Diagnostics GmbH, founded in 2018 and based in Munich, Germany, specializes in the manufacturing of digital data fingerprints for human blood samples. The company has developed a device designed for precise measurement and analysis of blood samples, contributing to advancements in medical diagnostics. By focusing on innovative solutions in the healthcare sector, Smart4Diagnostics aims to enhance the accuracy and efficiency of blood analysis, thereby improving patient outcomes.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Novus Diagnostics develops a point-of-care diagnostic system for infectious diseases, including a sample-to-answer sepsis platform that rapidly detects and classifies pathogens in whole blood. The device provides automated pathogen identification within minutes from a blood sample, allowing healthcare providers to diagnose sepsis-related infections and initiate timely, cost-effective treatment.

Mode Sensors AS is a digital healthcare company based in Trondheim, Norway, specializing in hydration monitoring technology. Founded in 2016, the company has developed innovative wearable solutions, notably its flagship product, Re:Balans®, which allows for real-time, non-invasive tracking of fluid balance. This technology is designed to assist healthcare providers in assessing patients' hydration status, enabling early intervention and improved health outcomes. Mode Sensors' solutions are applicable across various sectors, including healthcare, defense, and workforce safety, and they integrate with existing remote patient monitoring systems. By focusing on user-friendly design and continuous innovation, Mode Sensors aims to optimize hydration management and enhance overall well-being and performance in diverse environments.

KinePict develops medical imaging technology that enhances image quality in interventional radiology while reducing contrast agent and radiation exposure. Its proprietary technologies include Digital Variance Angiography, ultrafast cubic spline-fit algorithms, and real-time non-rigid motion correction, enabling safer procedures, more accurate diagnostics, and improved patient outcomes.

KinePict develops medical imaging technology that enhances image quality in interventional radiology while reducing contrast agent and radiation exposure. Its proprietary technologies include Digital Variance Angiography, ultrafast cubic spline-fit algorithms, and real-time non-rigid motion correction, enabling safer procedures, more accurate diagnostics, and improved patient outcomes.

Mode Sensors AS is a digital healthcare company based in Trondheim, Norway, specializing in hydration monitoring technology. Founded in 2016, the company has developed innovative wearable solutions, notably its flagship product, Re:Balans®, which allows for real-time, non-invasive tracking of fluid balance. This technology is designed to assist healthcare providers in assessing patients' hydration status, enabling early intervention and improved health outcomes. Mode Sensors' solutions are applicable across various sectors, including healthcare, defense, and workforce safety, and they integrate with existing remote patient monitoring systems. By focusing on user-friendly design and continuous innovation, Mode Sensors aims to optimize hydration management and enhance overall well-being and performance in diverse environments.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

SwissDeCode is a Swiss company based in Renens that specializes in food safety and compliance services for food manufacturers. Founded in 2016, it offers rapid onsite DNA testing solutions that allow production facilities to confirm food authenticity, safety, and origin. By providing plug-and-play systems, SwissDeCode enables factories to obtain food safety and quality certifications within the same work shift, facilitating immediate decision-making for inspectors. This approach not only addresses contamination threats but also transforms them into sustainable opportunities for food producers.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.